

# Giulia Carla C Marchetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4549246/publications.pdf>

Version: 2024-02-01

164  
papers

5,262  
citations

101496

36  
h-index

102432

66  
g-index

169  
all docs

169  
docs citations

169  
times ranked

6743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Microbial Translocation in the Pathogenesis of HIV Infection and AIDS. <i>Clinical Microbiology Reviews</i> , 2013, 26, 2-18.	5.7	404
2	Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. <i>Aids</i> , 2008, 22, 2035-2038.	1.0	256
3	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. <i>Lancet HIV</i> , 2015, 2, e98-e106.	2.1	249
4	Female gender is associated with long COVID syndrome: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 611.e9-611.e16.	2.8	230
5	Early Impairment of Gut Function and Gut Flora Supporting a Role for Alteration of Gastrointestinal Mucosa in Human Immunodeficiency Virus Pathogenesis. <i>Journal of Clinical Microbiology</i> , 2008, 46, 757-758.	1.8	191
6	The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options. <i>Clinical Infectious Diseases</i> , 2009, 48, 328-337.	2.9	163
7	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naïve patients with high CD4+ cell count. <i>Aids</i> , 2011, 25, 1385-1394.	1.0	155
8	The Absence of CD4+ T Cell Count Recovery Despite Receipt of Virologically Suppressive Highly Active Antiretroviral Therapy: Clinical Risk, Immunological Gaps, and Therapeutic Options. <i>Clinical Infectious Diseases</i> , 2009, 48, 328-337.	2.9	150
9	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2015, 211, 178-186.	1.9	146
10	Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. <i>Aids</i> , 2006, 20, 1727-1736.	1.0	127
11	Molecular Epidemiology Study of Exogenous Reinfection in an Area with a Low Incidence of Tuberculosis. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2213-2218.	1.8	123
12	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	3.9	119
13	Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy. <i>Journal of Medical Virology</i> , 2021, 93, 1175-1179.	2.5	115
14	Evaluation of PCR in Detection of <i>Mycobacterium tuberculosis</i> from Formalin-Fixed, Paraffin-Embedded Tissues: Comparison of Four Amplification Assays. <i>Journal of Clinical Microbiology</i> , 1998, 36, 1512-1517.	1.8	111
15	Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. <i>AIDS Research and Therapy</i> , 2016, 13, 19.	0.7	105
16	Monitoring of Transmission of Tuberculosis between Wild Boars and Cattle: Genotypical Analysis of Strains by Molecular Epidemiology Techniques. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2766-2771.	1.8	98
17	Evidence for Polymicrobial Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy. <i>PLoS ONE</i> , 2011, 6, e18580.	1.1	97
18	Spoligotyping and <i>Mycobacterium tuberculosis</i> . <i>Emerging Infectious Diseases</i> , 2005, 11, 1242-1248.	2.0	80

#	ARTICLE	IF	CITATIONS
19	Detection of T cell receptor circles (TRECs) as biomarkers for de novo T cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA). <i>Journal of Immunological Methods</i> , 2000, 237, 187-197.	0.6	78
20	Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. <i>Aids</i> , 2013, 27, 769-779.	1.0	70
21	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	1.3	68
22	Low-Dose Prolonged Intermittent Interleukin-2 Adjuvant Therapy: Results of a Randomized Trial among Human Immunodeficiency Virus-Positive Patients with Advanced Immune Impairment. <i>Journal of Infectious Diseases</i> , 2002, 186, 606-616.	1.9	63
23	T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis. <i>PLoS ONE</i> , 2012, 7, e46073.	1.1	61
24	Nosocomial Bacterial Pneumonia in HIV-Infected Patients: Risk Factors for Adverse Outcome and Implications for Rational Empiric Antibiotic Therapy. <i>Infection</i> , 2006, 34, 9-16.	2.3	57
25	Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy. <i>Aids</i> , 2016, 30, 991-1003.	1.0	55
26	CD4+ T Cell Depletion, Immune Activation and Increased Production of Regulatory T Cells in the Thymus of HIV-Infected Individuals. <i>PLoS ONE</i> , 2010, 5, e10788.	1.1	51
27	Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. <i>Journal of Translational Medicine</i> , 2013, 11, 51.	1.8	48
28	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNA cohort. <i>Journal of the International AIDS Society</i> , 2019, 22, e25227.	1.2	46
29	Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness. <i>Frontiers in Immunology</i> , 2020, 11, 580987.	2.2	46
30	Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. <i>Antiviral Therapy</i> , 2009, 14, 321-330.	0.6	41
31	Mediterranean leishmaniasis in HIV-infected patients: Epidemiological, clinical, and diagnostic features of 22 cases. <i>Infection</i> , 1998, 26, 93-99.	2.3	40
32	Immune response in children with COVID-19 is characterized by lower levels of T-cell activation than infected adults. <i>European Journal of Immunology</i> , 2020, 50, 1412-1414.	1.6	40
33	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 263-271.	0.9	39
34	Plasmacytoid Dendritic Cells Depletion and Elevation of IFN- $\beta$ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 654587.	2.2	39
35	Effectiveness Of Aminosidine (Paromomycin) Sulfate In Chronic Cryptosporidium Diarrhea In Aids Patients: An Open, Uncontrolled, Prospective Clinical Trial. <i>Journal of Infectious Diseases</i> , 1994, 170, 1349-1350.	1.9	38
36	Nested Polymerase Chain Reaction for <i>Mycobacterium tuberculosis</i> IS6110 Sequence on Formalin-Fixed Paraffin-Embedded Tissues With Granulomatous Diseases for Rapid Diagnosis of Tuberculosis. <i>American Journal of Clinical Pathology</i> , 1998, 109, 411-415.	0.4	37

#	ARTICLE	IF	CITATIONS
37	Does fluvastatin favour HCV replication <i>in vivo</i> ? A pilot study on HIV/HCV coinfecting patients. <i>Journal of Viral Hepatitis</i> , 2009, 16, 479-484.	1.0	36
38	Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e80157.	1.1	35
39	Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 401-409.	1.3	34
40	Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients. <i>PLoS ONE</i> , 2012, 7, e32028.	1.1	34
41	Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. <i>Aids</i> , 2010, 24, 1455-1460.	1.0	33
42	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. <i>Clinical Microbiology and Infection</i> , 2016, 22, 288.e1-288.e8.	2.8	33
43	A case of Austrian's syndrome with ocular involvement. <i>Infection</i> , 1999, 27, 46-47.	2.3	31
44	Stimulation of PBMC and Monocyte-Derived Macrophages via Toll-Like Receptor Activates Innate Immune Pathways in HIV-Infected Patients on Virally Suppressing Combination Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2016, 7, 614.	2.2	30
45	Pegylated Interferon- $\alpha$ -Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1910-1917.	2.9	30
46	A Case of Costochondral Abscess due to <i>Corynebacterium minutissimum</i> in an HIV-infected Patient. <i>Journal of Infection</i> , 2000, 41, 103-105.	1.7	28
47	Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 1271-1279.	2.0	25
48	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. <i>BMC Medicine</i> , 2018, 16, 79.	2.3	24
49	Comparison between spoligotyping and IS6110 restriction fragment length polymorphisms in molecular genotyping analysis of <i>Mycobacterium tuberculosis</i> strains. <i>Molecular and Cellular Probes</i> , 2005, 19, 236-244.	0.9	23
50	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. <i>BMC Infectious Diseases</i> , 2014, 14, 79.	1.3	23
51	Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. <i>Aids</i> , 2004, 18, 211-216.	1.0	22
52	Use of the FRAX Equation as First-Line Screening of Bone Metabolism Alteration in the HIV-Infected Population. <i>Journal of Infectious Diseases</i> , 2010, 202, 330-331.	1.9	22
53	Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5925.	1.8	22
54	Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers. <i>EClinicalMedicine</i> , 2021, 36, 100914.	3.2	22

#	ARTICLE	IF	CITATIONS
55	Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy. <i>Aids</i> , 2010, 24, 2590-2593.	1.0	21
56	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1363-1367.	1.3	21
57	Role of <i>In Vitro</i> Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	20
58	Assessment of radiological vertebral fractures in HIV-infected patients: clinical implications and predictive factors. <i>HIV Medicine</i> , 2015, 16, 563-571.	1.0	20
59	Association Between Impaired V $\beta$ 7.2+CD161++CD8+ (MAIT) and V $\beta$ 7.2+CD161-CD8+ T-Cell Populations and Gut Dysbiosis in Chronically HIV- and/or HCV-Infected Patients. <i>Frontiers in Microbiology</i> , 2019, 10, 1972.	1.5	20
60	Noncirrhotic Portal Hypertension in HIV-Infected Patients: A Case Control Evaluation and Review of the Literature. <i>AIDS Patient Care and STDs</i> , 2010, 24, 697-703.	1.1	19
61	CD8 T-Cell Activation Is Associated With Lipodystrophy and Visceral Fat Accumulation in Antiretroviral Therapy-Treated Virologically Suppressed HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 360-366.	0.9	19
62	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. <i>BMC Public Health</i> , 2018, 18, 870.	1.2	19
63	CD8+ Hyperactivation and Senescence Correlate With Early Carotid Intima-Media Thickness in HIV+ Patients With No Cardiovascular Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 642-644.	0.9	18
64	Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes. <i>Frontiers in Immunology</i> , 2021, 12, 639291.	2.2	18
65	A PCR-Colorimetric Microwell Plate Hybridization Assay for Detection of <i>Mycobacterium tuberculosis</i> and <i>M. avium</i> from Culture Samples and Ziehl-Neelsen-Positive Smears. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1772-1776.	1.8	18
66	Cutaneous Infection Caused by <i>Mycobacterium gordonae</i> in a Human Immunodeficiency Virus-Infected Patient Receiving Antimycobacterial Treatment. <i>Clinical Infectious Diseases</i> , 1997, 25, 1490-1491.	2.9	17
67	Increased Bone Marrow Interleukin-7 (IL-7)/IL-7R Levels but Reduced IL-7 Responsiveness in HIV-Positive Patients Lacking CD4+ Gain on Antiviral Therapy. <i>PLoS ONE</i> , 2010, 5, e15663.	1.1	16
68	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 735-741.	1.3	16
69	Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 347-352.	0.9	16
70	Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients. <i>PLoS ONE</i> , 2010, 5, e14119.	1.1	16
71	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV Infection (IN ACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	1.4	16
72	Immunophenotype and Function of CD38-Expressing CD4+ and CD8+ T Cells in HIV-Infected Patients Undergoing Suppressive Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 1511-1513.	1.9	15

#	ARTICLE	IF	CITATIONS
73	Time spent with HIV-RNA $\geq 200$ copies/ml in a cohort of people with HIV during the U=U era. <i>Aids</i> , 2021, 35, 1103-1112.	1.0	15
74	Successful Rescue Therapy with a Darunavir/Ritonavir and Etravirine Antiretroviral Regimen in a Child with Vertically Acquired Multidrug-Resistant HIV-1. <i>Antiviral Therapy</i> , 2008, 13, 839-843.	0.6	15
75	Cardiovascular disease in women with HIV-1 infection. <i>International Journal of Cardiology</i> , 2017, 241, 50-56.	0.8	14
76	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3295-3304.	1.3	14
77	Tumor Necrosis Factor- $\alpha$ Increased Production during Thalidomide Treatment in Patients with Tuberculosis and Human Immunodeficiency Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2000, 182, 639-639.	1.9	13
78	Successful direct-acting antiviral therapy in HIV/HCV coinfected patients fails to restore circulating mucosal-associated invariant T cells. <i>European Journal of Immunology</i> , 2019, 49, 1127-1129.	1.6	13
79	Specific detection of <i>Mycobacterium tuberculosis</i> by mtp40 nested PCR. <i>Journal of Clinical Microbiology</i> , 1996, 34, 2866-2867.	1.8	13
80	Immunomodulation Induced by Tucaresol in HIV Infection: Results of a 16 Week Pilot Phase I/II Trial. <i>Antiviral Therapy</i> , 2004, 9, 603-614.	0.6	13
81	Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-10.	0.3	12
82	Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN $\alpha$ add-on strategy: A randomized study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 381-390.	1.0	12
83	Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?. <i>HIV Medicine</i> , 2021, 22, 140-145.	1.0	12
84	IL-7/IL-7 Receptor System Regulation following IL-2 Immunotherapy in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2004, 9, 447-452.	0.6	12
85	HIV-infected long-term nonprogressors display a unique correlative pattern between the interleukin-7/interleukin-7 receptor circuit and T-cell homeostasis. <i>HIV Medicine</i> , 2009, 10, 422-431.	1.0	11
86	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. <i>Clinical Microbiology and Infection</i> , 2017, 23, 267.e1-267.e4.	2.8	11
87	Immune Reconstitution in HIV+ Subjects on Lopinavir/Ritonavir-Based HAART According to the Severity of Pre-Therapy CD4+. <i>Current HIV Research</i> , 2012, 10, 597-605.	0.2	11
88	Clinical and Immunological Improvement in a Patient Who Received Thalidomide Treatment for Refractory <i>Mycobacterium avium</i> Complex Infection. <i>Clinical Infectious Diseases</i> , 1998, 26, 184-185.	2.9	10
89	Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy-Experienced Patients: A Multicenter Clinical Experience. <i>HIV Clinical Trials</i> , 2014, 15, 140-150.	2.0	10
90	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 50$ copies/mL. <i>Infection</i> , 2017, 45, 521-528.	2.3	10



#	ARTICLE	IF	CITATIONS
91	Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. <i>BMC Infectious Diseases</i> , 2019, 19, 881.	1.3	10
92	Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease. <i>Aids</i> , 2000, 14, 1859-1861.	1.0	10
93	Molecular epidemiology characterization of a multidrug-resistant <i>Mycobacterium bovis</i> outbreak amongst HIV-positive patients. <i>Aids</i> , 1998, 12, 445-6.	1.0	10
94	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
95	The human thymus: A new perspective on thymic function, aging, and hiv infection. <i>Clinical Immunology Newsletter</i> , 1999, 19, 65-79.	0.1	8
96	Immunological Mechanisms of Interleukin-2 (IL-2) Treatment in HIV/AIDS Disease. <i>Current Molecular Pharmacology</i> , 2009, 2, 40-45.	0.7	8
97	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3460-3470.	1.3	8
98	Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa340.	0.4	8
99	Untangling the Immunological Implications of Nadir on CD4+ Cell Recovery during Suppressive Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 46, 149-150.	2.9	7
100	The Challenge of IL-2 Immunotherapy in HIV Disease: &#x201C;No through Road&#x201D; or Turning Point?. <i>Current HIV Research</i> , 2008, 6, 189-199.	0.2	7
101	HIV-Infected Late Presenter Patients. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-2.	0.3	7
102	HPV Infection in a Cohort of HIV-Positive Men and Women: Prevalence of Oncogenic Genotypes and Predictors of Mucosal Damage at Genital and Oral Sites. <i>Journal of Sexually Transmitted Diseases</i> , 2013, 2013, 1-8.	1.0	7
103	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015, 10, e0124252.	1.1	7
104	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015, 10, e0140877.	1.1	7
105	Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. <i>AIDS Patient Care and STDs</i> , 2017, 31, 487-494.	1.1	7
106	Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study. <i>Antibiotics</i> , 2021, 10, 1031.	1.5	7
107	Predictors of low ovarian reserve in cART-treated women living with HIV. <i>Medicine (United States)</i> , 2021, 100, e27157.	0.4	7
108	PCR-Hybridization Assay for <i>Mycobacterium avium</i> Complex: Optimization of Detection in Peripheral Blood from Humans. <i>Journal of Clinical Microbiology</i> , 2001, 39, 1638-1643.	1.8	6

#	ARTICLE	IF	CITATIONS
109	Rhodococcus equi infection in a patient with spinocellular carcinoma of unknown origin. Journal of Medical Microbiology, 2008, 57, 1431-1433.	0.7	6
110	Abacavir and Cardiovascular Risk in HIV-Infected Patients: Does T Lymphocyte Hyperactivation Exert a Pathogenic Role?. Clinical Infectious Diseases, 2008, 47, 1495-1496.	2.9	6
111	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	1.3	6
112	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. HIV Medicine, 2020, 21, 523-535.	1.0	6
113	Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment. PLoS ONE, 2014, 9, e110287.	1.1	6
114	Detrimental Effect of Atazanavir Plasma Concentrations on Total Serum Bilirubin Levels in the Presence of UGT1A1 Polymorphisms. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e96-e97.	0.9	5
115	Highlights on HIV eradication in 2013. Aids, 2014, 28, 1-7.	1.0	5
116	T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside retrotranscriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study. Antiviral Therapy, 2015, 21, 133-142.	0.6	5
117	Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients. Aids, 2017, 31, 311-314.	1.0	5
118	Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature. BMC Infectious Diseases, 2018, 18, 8.	1.3	5
119	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS ONE, 2016, 11, e0160761.	1.1	5
120	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. AIDS Reviews, 2017, 19, .	0.5	5
121	Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice. BMC Infectious Diseases, 2021, 21, 1132.	1.3	5
122	Fully Immunocompetent CD8+ T Lymphocytes Are Present in Autologous Haematopoietic Stem Cell Transplantation Recipients Despite an Ineffectual T-Helper Response. PLoS ONE, 2008, 3, e3616.	1.1	4
123	Sequencing of Bacterial Microflora in Peripheral Blood: our Experience with HIV-infected Patients. Journal of Visualized Experiments, 2011, , .	0.2	4
124	Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the ICONA Foundation cohort. HIV Medicine, 2015, 16, 412-420.	1.0	4
125	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 465-471.	0.9	4
126	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. BMC Infectious Diseases, 2021, 21, 557.	1.3	4



#	ARTICLE	IF	CITATIONS
127	Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepalCONA Foundation Cohort Study. <i>Viruses</i> , 2021, 13, 1402.	1.5	4
128	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. <i>PLoS ONE</i> , 2017, 12, e0189045.	1.1	4
129	Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19. <i>Vaccines</i> , 2022, 10, 550.	2.1	4
130	Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 997-1004.	2.0	4
131	Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). <i>Journal of NeuroVirology</i> , 2018, 24, 679-694.	1.0	3
132	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 443-456.	2.0	3
133	Immunomodulation induced by tucarecol in HIV infection: results of a 16 week pilot Phase I/II trial. <i>Antiviral Therapy</i> , 2004, 9, 603-14.	0.6	3
134	T-Cell Subsets (T, T, T) and Poly-Functional Immune Response in Patients with Human Immunodeficiency Virus (HIV) Infection and Different T-CD4 Cell Response. <i>Annals of Clinical and Laboratory Science</i> , 2019, 49, 519-528.	0.2	3
135	Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patients. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2020, 34, 1553 -1559.	0.7	3
136	Delayed-Type Hypersensitivity Skin Testing Can Predict CD4 Count Increase in HIV Patients With Poor Immunologic Response to HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 277-278.	0.9	2
137	CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19509.	1.2	2
138	Brief Report: Drop in CD4+ Counts Below 200 Cells/ $\mu$ L After Reaching (or Starting From) Values Higher than 350 Cells/ $\mu$ L in HIV-Infected Patients With Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 417-422.	0.9	2
139	Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy. <i>Antiviral Therapy</i> , 2018, 23, 633-637.	0.6	2
140	Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. <i>HIV Clinical Trials</i> , 2018, 19, 158-162.	2.0	2
141	Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study. <i>Clinical Drug Investigation</i> , 2019, 39, 1239-1249.	1.1	2
142	Biomarkers of aging in HIV: inflammation and the microbiome. <i>European Geriatric Medicine</i> , 2019, 10, 175-182.	1.2	2
143	Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study. <i>BMC Infectious Diseases</i> , 2020, 20, 812.	1.3	2
144	Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect. <i>Journal of Chemotherapy</i> , 2021, 33, 238-244.	0.7	2

#	ARTICLE	IF	CITATIONS
145	Persistence of High Peripheral Activated CD8+ T-cells and Not a Low CD4:CD8 Ratio Predict cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac046.	0.4	2
146	Immunomodulants in HIV infection. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 1115-1131.	2.4	1
147	Sudden Cardiac Death in a Young HIV-Positive Man on Effective Antiretroviral Therapy. <i>Current HIV Research</i> , 2008, 6, 560-562.	0.2	1
148	Serum $\beta$ -Fetoprotein Levels Predict Early Virologic Response in HIV-Positive Subjects Treated for Chronic Hepatitis C. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 361-363.	0.9	1
149	Factors associated with HPV-DNA clearance in a cohort of HIV-positive patients: role of cART and gender. <i>Journal of the International AIDS Society</i> , 2014, 17, 19717.	1.2	1
150	Cell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus-Related Anal Dysplastic Lesions. <i>Clinical Infectious Diseases</i> , 2016, 63, 1396-1398.	2.9	1
151	Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression. <i>PLoS ONE</i> , 2019, 14, e0212075.	1.1	1
152	Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss. <i>Scientific Reports</i> , 2021, 11, 9632.	1.6	1
153	The fecal microbiome directly drives immune activation in HIV infection. <i>Annals of Translational Medicine</i> , 2018, 6, S45-S45.	0.7	1
154	SARS-CoV-2 and the nervous system: review on pathogenesis of nervous system SARS-CoV-2 damage. , 0, , .		1
155	IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients. <i>Antiviral Therapy</i> , 2004, 9, 447-52.	0.6	1
156	Use of multiplex PCR assay and DNA fingerprinting analysis for typing of multidrug-resistant <i>Mycobacterium tuberculosis</i> strains. <i>Journal of Infection</i> , 1997, 35, 322-323.	1.7	0
157	Effective nocturnal oxygen therapy increases circulating level of tumor necrosis factor- $\beta$ in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 64-67.	0.6	0
158	A 20-year-old girl with an unusual febrile illness. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	0
159	Renal microsporidiosis due to <i>Encephalitozoon cuniculi</i> in an HIV/AIDS patient with persistent fever and kidney injury. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1439-1440.	2.8	0
160	A Quantitative Estimate of the Expected Shortening of the Median Isolation Period of Patients With COVID-19 After the Adoption of a Symptom-Based Strategy. <i>Frontiers in Public Health</i> , 2021, 9, 639347.	1.3	0
161	Women are from venus: implications for diversified sex-based preexposure prophylaxis approaches. <i>Aids</i> , 2021, 35, 1691-1693.	1.0	0
162	Lack of HIV seroconversion in a patient treated immediately with antiretroviral therapy at acute infection and virus relapse. <i>Aids</i> , 2021, 35, 1708-1710.	1.0	0

#	ARTICLE	IF	CITATIONS
163	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS ONE, 2016, 11, e0156360.	1.1	0
164	Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. New Microbiologica, 2019, 42, 69-80.	0.1	0